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Psycho‐Oncology. 2019;1–9.Abstract
Objective: In line with screening guidelines, cancer survivors were consecutively
screened on depressive symptoms (as part of standard care), with those reporting ele-
vated levels of symptoms offered psychological care as part of a trial. Because of the
low uptake, no conclusions could be drawn about the interventions' efficacy. Given
the trial set‐up (following screening guidelines and strict methodological quality
criteria), we believe that this observational study reporting the flow of participation,
reasons for and characteristics associated with nonparticipation, adds to the debate
about the feasibility and efficiency of screening guidelines.
Methods: Two thousand six hundred eight medium‐ to long‐term cancer survivors
were consecutively screened on depressive symptoms using the Patient Health
Questionnaire‐9 (PHQ‐9). Those with moderate depressive symptoms (PHQ‐
9 ≥ 10) were contacted and informed about the trial. Patient flow and reasons for
nonparticipation were carefully monitored.
Results: One thousand thirty seven survivors (74.3%) returned the questionnaire,
with 147 (7.6%) reporting moderate depressive symptoms. Of this group, 49 survivors
(33.3%) were ineligible, including 26 survivors (17.7%) already receiving treatment
and another 44 survivors (30.0%) reporting no need for treatment. Only 25 survivors
(1.0%) participated in the trial.
Conclusion: Of the approached survivors for screening, only 1% was eligible and
interested in receiving psychological care as part of our trial. Four reasons for nonpar-
ticipation were: nonresponse to screening, low levels of depressive symptoms, no
need, or already receiving care. Our findings question whether to spend the limited
resources in psycho‐oncological care on following screening guidelines and the
efficiency of using consecutive screening for trial recruitment in cancer survivors.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Depressive symptoms are common in cancer patients, not only shortly
after diagnosis or during active treatment but also in cancer survi-
vors.1,2 As effective psychological interventions exist to treat these
symptoms,3-6 clinical guidelines currently recommend to routinely
screen cancer patients on distress throughout the illness and treat-
ment trajectory in order to detect distress and refer patients accord-
ingly to additional care.7,8 These recommendations still hold, even
though so far no well‐conducted randomized control trials (RCTs) have
demonstrated that mental health outcomes improve via these screen-
ing programs.9
Evidence for the efficacy on interventions has mostly been con-
firmed in patients in the short‐term phase and women with breast
cancer, whereas less evidence is available for the efficacy of these
interventions among cancer survivors.3-6,10-12 Therefore, the Dutch
Cancer Foundation released a call in 2013 for more evidence regard-
ing the efficacy of psychological interventions among (nonbreast) can-
cer survivors. Following strict high‐quality standards,13 including
consecutively screening on depressive symptoms, we set up a multi-
center RCT examining the efficacy of cognitive behavioral therapy
(CBT) and mindfulness‐based cognitive therapy (MBCT) for treating
depressive symptoms in cancer survivors. Because of the low trial par-
ticipation, no conclusion could be drawn about the efficacy of the
interventions. As a means to reflect on reasons why an RCT following
high‐quality methodological standards failed to work in clinical prac-
tice, this observational study examined the reasons for nonparticipa-
tion in the RCT and the demographic and medical characteristics of
depressed survivors that did (not) participate. Cancer survivors in our
trial were consecutively screened on depressive symptoms as a part
of standard care, as recommended by the current clinical screening
guidelines7,8 and regarded as a quality standard in setting up an
RCT.14,15 Yet, the screening procedure was not efficient (ie, resulting
in low uptake). Findings of our study may therefore add to the debate
regarding the feasibility and efficiency of current screening guidelines
for identifying patients in need for care. Our aim is twofold1: to inform
clinical practice about cancer survivors' levels of depressive symptoms
and care needs and the use of consecutive screening2; to inform
researchers in setting up future psychological RCTs in cancer survi-
vors, to carefully reflect and make considerations regarding the use
of consecutive and convenience sampling as a means for patient
recruitment.2 | METHOD
2.1 | Study design
This observational study used data collected as part of a multicenter
RCT comparing MBCT and CBT with treatment as usual (TAU). For
the current study, only the screening data was used. Data were col-
lected from February 2015 until May 2017.2.2 | Participants
Eligibility criteria for being approached for screening were: a cancer
diagnosis (except breast cancer), age between 18 to 75 years at the
time of diagnosis, currently no active cancer, and completion of cura-
tive treatment 1 to 5 years ago. For trial participation, an additional eli-
gibility criterion was the report of moderate levels of depressive
symptoms (PHQ‐9 ≥ 10). Exclusion criteria for trial participation were:
not being able to read and write Dutch, having psychiatric comorbid-
ity, receiving psychological treatment for depressive symptoms (cur-
rently or less than 2 months ago) and an instable antidepressant
regimen (ie, starting/changing less than 2 months ago).2.3 | Screening procedure
Individualswere routinely screened for depressive symptoms at depart-
ments radiotherapy, surgery, oral and maxillofacial surgery, gynecology,
hematology, endocrinology, medical oncology, and colorectal surgery.
Individuals received a letter from their department inviting them to
complete a mood questionnaire (PHQ‐9) on paper or online and in case
this score was elevated, they would be contacted. Individuals reporting
elevated depressive symptoms (PHQ‐9 ≥ 10) received feedback about
their elevated levels and were informed that they would receive a tele-
phone call to discuss the depressive symptoms and a possible need for
psychological support. These telephonic interviews were executed by
graduate clinical psychologists or research/student assistants who had
received special training, in which they made a clinical assessment of
the psychological problems. Subsequently, persons were selected on
eligibility (using a standardized interview to check for exclusion criteria),
interest in psychological support and willingness to participate. If this
was the case, they received written information about the trial, a ques-
tionnaire, an informed consent form, and a prepaid return envelope.
They were asked to return a completed informed consent and
VAN DER DONK ET AL. 3questionnaire within 2weeks. Individuals expressing interest in psycho-
logical support but who were ineligible or unwilling to participate were
given advice to discuss their care needs with their medical specialist or
general practitioner.2.4 | Variables
For screening on depressive symptoms, the Patient Health
Questionnaire‐9 (PHQ‐9) was used,16 which is a self‐report screening
tool based on the nine depression criteria according to the Diagnostic
and Statistical Manual of Mental Disorders. Each item can be scored from
0 (not at all) to 3 (nearly every day), resulting in total scores ranging from
0 to 27, with higher scores indicating more depressive symptoms.2.5 | Statistical analyses
SPSS 25.0 was used for executing statistical analyses. Demographic
(ie, age and gender) and cancer‐related characteristics (ie, years since
diagnosis, years since treatment, cancer type, treatment type andFIGURE 1 Flowchart of participant
recruitment and flow through the study. PHQ,
patient health questionnaire; CBT, cognitive
behavioral therapy; MBCT, mindfulness‐based
cognitive therapy; TAU, treatment as usualrecurrence) were calculated. Chi‐square tests and t‐tests compared
groups (ie, respondents versus nonrespondents; depressed versus
not depressed; in trial versus not in trial) on demographic and
cancer‐related variables.3 | RESULTS
Initially 2608 cancer survivors were invited to complete a screening
questionnaire (Figure 1). In total 25 individuals agreed to participate
in the RCT, which was 1.0% of the approached individuals.
Of the 2608 cancer survivors approached for routine screening,
1937 returned a valid questionnaire. Table 1 describes the demo-
graphic and cancer‐related characteristics of the 1937 cancer survi-
vors. Mean age was 63 years with 61% being male. Average time
since diagnosis and time since treatment were both 3 years. Most
common cancer type was gastro‐intestinal cancer and only receiving
surgery was the most common treatment. In total, 166 individuals
(8.6%) reported a cancer recurrence.
Those 1937 persons who returned the questionnaire were com-
pared with those who did not return it. Compared with those who





Age (M, SD) 63.34 10.33
Gender, male (N, %) 1188 61.3
Cancer‐related variables
Years since diagnosis (M, SD) 3.40 1.31
Years since diagnosis (N, %)
≤ 2 y 591 30.5
> 2 y 1346 69.5
Years since end treatment (M, SD) 3.07 1.24
Years since end treatment (N, %)
1 y 218 11.3
2 y 523 27.0
3 y 468 24.2
4 y 397 20.5
5 y 330 17.0
Cancer type (N, %)
Lung 70 3.6
Skin 35 1.8





Bone & soft tissue 43 2.2
Hematological 160 8.3
Other/primary unknown 9 0.5
Received treatment (N, %)
Surgery 429 22.2
Surgery + RT 372 19.2
Surgery + chemotherapy 180 9.3
Surgery + RT + chemotherapy 211 10.9
RT 385 19.9
RT + chemotherapy 196 10.1






Abbreviation: RT, radiation therapy. Numbers may slightly differ because of
missing variables.
4 VAN DER DONK ET AL.did not return the questionnaire, cancer survivors returning the ques-
tionnaire were significantly older (63.3 years ±10.3 versus 59.4 years
±13.0), more often male (61% versus 53%) and had more often acancer recurrence (8.6% versus 4.8%). No significant differences were
found in years since diagnosis or years since treatment. Concerning
cancer site, highest response rates were found among survivors with
bone and soft tissue (91.5%) and survivors with urological cancer
(88.4%) with lowest response rates among lung cancer survivors
(65.4%). A full overview regarding response rates and elevated depres-
sive symptoms (PHQ‐9 ≥ 10) according to demographic and cancer‐
related characteristics can be found in the Appendix.
In total, 147 persons reported moderate levels of depressive symp-
toms (PHQ ≥ 10) and these persons were compared with those 1790
persons not depressed. Those depressed were significantly younger
(63.7 ± 10.1 versus 59.3 ± 11.9) compared with those not depressed.
No significant differences between those survivors with or without
moderate levels of depressive symptoms were found for gender, year
since diagnosis, year since treatment, and cancer recurrence. Highest
levels of depressive symptoms were found among lung cancer survi-
vors (17.1%) and lowest levels of depressive symptoms among gastro-
intestinal cancer survivors (3.9%).
Table 2 describes a comparison between 122 individuals with ele-
vated levels of depressive symptoms not included in the trial versus
25 individuals with elevated levels of depressive symptoms who partic-
ipated in the trial. No significant differences were found between these
groups on age, gender, depressive symptoms, time since diagnosis, time
since treatment, or cancer recurrence.3.1 | Reasons for nonparticipation
Four major reasons for nonparticipation were identified. The first rea-
son was not responding to the screening questionnaire, with 671
persons (25.7% of 2608 cancer survivors) not returning a valid ques-
tionnaire. Secondly, low rates of depressive symptoms were observed,
with only 147 persons (ie, 7.6% of those completing screening) scoring
moderate levels of depressive symptoms. A third reason for nonpartic-
ipation involved low care needs, with 44 depressed persons (29.9% of
147) reporting no need or time for psychological care. A final reason
for not being able to participate was already receiving treatment,
reported by 26 depressed persons (17.7% of 147).4 | DISCUSSION
As part of an RCT, we screened a large group of cancer survivors on
depressive symptoms, with those reporting moderate or higher levels
of depressive symptoms being contacted to discuss their need for care,
and inform them about the possibility to receive psychological care, as
part of an intervention study. We encountered a very low participation
rate. The current paper examined the reasons for not participating, as
we believe this will provide more insight into the feasibility of routinely
screening for depressive symptoms in cancer survivors as well as of the
use of consecutive screening for recruiting cancer survivors for a psy-
chological RCT. Of the 2608 survivors approached, only 7.6% reported
moderate levels of depressive symptoms, and of those, almost 50%
reported no psychological care needs or already received treatment.
TABLE 2 Characteristics of individuals participating in the RCT compared with those with elevated depressive symptoms that did not participate
in the trial
Depressed, Not In Trial Depressed, In Trial Total P value
N (%) 122 (83.0%) 25 (17.0%) 147 (100%)
Age (M, SD) 59.93 ± 11.86 56.16 ± 11.71 59.29 ± 11.88 0.149
Gender (% male) 54.90 56.00 55.10 0.921
Depressive symptoms (M, SD) 14.42 ± 3.83 13.92 ± 3.67 14.33 ± 3.80 0.552
Time since diagnosis 3.38 ± 1.22 3.75 ± 1.25 3.45 ± 1.23 0.179
Time since treatment 3.03 ± 1.16 3.09 ± 1.07 3.04 ± 1.14 0.829
Recurrence (% yes) 10.70 20.00 12.20 0.194
VAN DER DONK ET AL. 5A key finding is that most cancer survivors reported no or only mild
levels of depressive symptoms (taking into account that we excluded
survivors of breast cancer who are known to be a group at risk for
depressive symptoms17,18). Another main finding is that many survivors
reporting elevated depressive symptoms were not interested in receiv-
ing psychological care. Our findings question whether consecutive
screening on depressive symptoms as part of standard clinical practice
(as recommended by clinical guidelines as well as research recommen-
dations for recruiting trial participants)7,8,14 is feasible among cancer
survivors and an efficient way to detect those with a need for care
and referral. Four major reasons for nonparticipation were identified1:
one in four cancer survivors did not return the screening question-
naire,2 rates of depressive symptomswere lower than expected accord-
ing to literature,3 one in three depressed cancer survivors did not wish
to receive psychological care, and4 a group of depressed cancer survi-
vors already found psychological help themselves.
One in four cancer survivors could not be screened on depressive
symptoms, a response rate of 75% that can be considered high when
using a survey19 andwhich is also somewhat higher than response rates
in other screening studies (varying from 63% to 68%) among cancer
patients using surveys.20-23 Research has shown that patients not
responding to a screening questionnaire are also more likely to not
show up for medical check‐ups, suggesting that these patients may in
general be difficult to reach.24 An explanation for the nonresponse to
screeningmay be the information given in the accompanied letter, using
words like “depressive symptoms” and informing patients that they
would be contacted in case an elevated score was reported (See
Appendix).
The screening identified only a small group of cancer survivors
(7.6%) reporting moderate levels of depressive symptoms. This sug-
gests that most cancer survivors are able to adapt and do not experi-
ence depressive symptoms in the years following curative treatment.
When comparing rates of depressive symptoms in cancer patients,
heterogeneity in prevalence rates can be observed, related, among
others, to differences in cancer type, time since diagnosis, and the spe-
cific screening instrument.1 Regarding cancer type, two reviews con-
cluded that women with breast cancer are at risk for depressive
symptoms,17,18 which could explain why rates in our study were lower
than expected, as women with breast cancer were not approached. In
fact, most cancer survivors in our study were diagnosed with gastro‐intestinal or urological cancer, which have been associated with lower
levels of depressive symptoms.17,20 Related to this, in contrast to most
previous research focusing on female survivors,1,17,18,25 more than
half (61%) of our sample were men that received only surgery. It has
been shown that male cancer survivors have lower levels of depres-
sive symptoms compared with women,21 and it can be argued that
because of a good prognosis and advances in targeted cancer treat-
ment, the impact of cancer treatment may have been reduced
throughout the years, which could also have resulted in relatively
low levels of depressive symptoms.26 Additionally, psychosocial sup-
port throughout the cancer trajectory has improved and cancer survi-
vors in our study have possibly received intensive psychosocial
support during cancer diagnosis and active treatment.
Concerning time since diagnosis, two meta‐analyses among cancer
patients found depressive symptoms to decrease over time, varying
from 27% (in the acute phase) to 21% (within the first year post‐
treatment), to 15% (at least 1 y post‐treatment), with similar levels as
healthy controls after 2 years following diagnosis.1,27 This could also
explain lower rates of depressive symptoms in our study, as cancer sur-
vivors were diagnosed and completed medical treatment on average
more than 3 years ago. When interpreting the above‐mentioned find-
ings, it should be taken into account that both meta‐analyses (like
meta‐analyses in general) have included a variety of screening instru-
ments, which hampers drawing firm conclusions regarding rates of
depressive symptoms. Generally, the efficacy of screening greatly
depends on the timing of the screening (ie, phase of the cancer trajec-
tory). In our study, we targeted medium‐ to long‐term cancer survivors
for screening, but if recently diagnosed cancer patients or those in
active treatment would have been approached, efficacy of screening
may have been higher (because of higher rates of depressive symptoms
and greater uptake).
Another factor that may explain variation in rates of depressive
symptoms is the measurement of symptoms, which includes the use
of a clinical diagnostic interview to classify major depressive disorder
versus self‐report screening questionnaires.1,28 Although screening
questionnaires are often used because of their convenience (ie, inex-
pensive and quick to administer to large groups), it should be noted that
screening questionnaires overestimate the prevalence of depression.28
In addition, variation in rates of depressive symptoms may not only be
explained by using different screening instruments but also by using
6 VAN DER DONK ET AL.different cutoff thresholds within a distinct instrument for determining
elevated depressive symptoms.1 Our study used the PHQ‐9, which is
commonly used in oncology for screening on depressive symp-
toms,16,20,21 and using a cut‐off of greater than or equal to 10, we found
moderate levels of depressive symptoms rates of 7.6%. Other studies
using the same criteria found similar, slightly higher percentages
(9.3%‐11.3%) for a mixed group of survivors.20,25 On the other hand,
some studies label mild depressive symptoms as being depressed.
Therefore, caution is warranted when comparing different rates across
studies and we recommend that future research includes a precise
description of what their rates of depressive symptoms refer to.
A third reason was low need for professional psychological care
among depressed cancer survivors. It is worth mentioning that in our
trial, care need was distinguished from willingness to participate in
the trial by asking this in separate questions. In our study, almost
one in three depressed persons reported no need or time for treat-
ment. Several studies have drawn similar conclusions that cancer
patients with elevated symptoms did not want a referral.29-32 Possible
reasons that have been identified include patients' desire to manage
problems on their own31,33,34 or by means of informal social sup-
port,30,31,33 which may be related to fear of stigmatization for visiting
a psychologist.30,33 Other reasons include that depressive symptoms
are not perceived as a severe burden for which professional help is
warranted34 or the preference for receiving medication (eg, antide-
pressants). Although there is evidence suggesting that patients with
a medical diagnosis prefer psychological treatment to antidepressant
medication,35 more research is needed to examine cancer survivors'
perceptions of and coping with depressive symptoms, their care
needs, and barriers to seek care in order to identify ways to improve
psycho‐oncological care.
A fourth reason was that cancer survivors already found profes-
sional psychological help themselves. In our study, this was 17.7%,
and similar percentages were reported by another Dutch trial among
cancer survivors 1 year after treatment29 and somewhat higher num-
bers (24%) by an Australian study on care needs in distressed cancer
patients.34 On the other hand, three Scottish high‐quality RCTs found
few depressed cancer patients to be already in treatment, varying
from 0.8% to 7.0%.36-38 A possible explanation for the relatively high
percentage of individuals already receiving treatment, as well as the
low care needs in our study, can be differences in healthcare policies
between countries in terms of insurance and coverage of psychosocial
aftercare for cancer survivors. For instance, in the Netherlands, this is
mostly covered by the insurance, making psychological care accessible
for anyone irrespective of trial participation. This could explain why
individuals in our trial reported low care needs and why the percent-
age of individuals already receiving treatment was substantial.
Currently, screening is recommended in clinical practice7,8 as well as
for trial recruitment,15 but in our trial screening (which was part of stan-
dard care) proved little effective in terms of detecting individuals with
care needs. Only 1.0% of the approached individuals participated in
the RCT. Several other trials on psychological outcomes in oncology
also found low inclusion rates between 2.5% and 3.5%.29,36 Above‐
mentioned trials and our trial used consecutive sampling for patientrecruitment, which encompasses systematically screening every indi-
vidual whomeets the selection criteria.14 Another frequently used sam-
pling method involves convenience sampling in which individuals are
recruited by means of (self)referral, which has advantages in terms of
cost, time, and logistics, butmay produce an unrepresentative sample.14
For this reason, consecutive sampling is generally seen as the golden
standard and is favorable to convenience sampling, because the latter
is more prone to selection bias.14 However, in practice, this may not
completely be the case, because a recent trial found that consecutive
sampling still resulted in considerable selection bias in terms of enrolling
predominantly young and highly educated patients.29 Moreover, con-
secutive sampling is not mandated in the CONSORT guidelines (recom-
mendations for high‐quality reporting of RCTs in order to maintain high
internal validity39) implying that consecutive sampling is not a preferred
method to convenience sampling for trial recruitment. Furthermore,
convenience sampling may result in general in higher motivation among
participants because of the self‐referral method.40 Given these consid-
erations and our finding that most cancer survivors were not depressed
and those that were did not want or already found help, it can be
debated whether the methodological advantages of consecutive sam-
pling outweigh its time and resource‐consuming procedures.40 We do
not presume either consecutive or convenience sampling to be a supe-
rior method, but instead recommend that in the future the trial's aims
and objectives should be decisive for choosing the appropriate sampling
method.4.1 | Study limitations
Findings of our study need to be set in the context of several limita-
tions. The first is that no information is available for nonresponders
regarding depression, so our findings can only be generalized to those
returning the questionnaire. Possibly among nonresponders, there
were depressed individuals that would have influenced rates of
depressive symptoms. Another limitation was the self‐report measure
of depressive symptoms, which may have resulted in not depressed
individuals (ie, false‐positives) being contacted or that false‐negatives
were not approached for help.4.2 | Clinical implications
Our findings suggest that screening cancer survivors consecutively on
depressive symptoms as part of standard care was not effective for
recruitment in a psychological trial. Of the initially approached cancer
survivors, 99% was ineligible, unwilling to participate, or could not be
reached. Major reasons for nonparticipation included nonresponse to
screening, low rates of depressive symptoms, low care needs, or
already receiving psychological treatment. Overall, given the minimal
gain from routine screening as suggested by our findings as well as
previous research,9 it can be questioned whether the required
resources would seem better spent on providing inexpensive or free
resources to those who need them or on providing psychological edu-
cation to patients. These findings should be considered when
VAN DER DONK ET AL. 7designing future psychological trials in cancer survivors or when
screening (for patient recruitment) is considered.
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APPENDIX
A.1. | Response rates and elevated depressive
symptoms (PHQ‐9 ≥ 10) according to demographic
and cancer‐related characteristicsCharacteristic Response Rate, % Elevated Scorec, %Agea<57 62.6 12.257‐66 75.8 9.466‐70 80.4 4.6>70 78.0 5.1GenderMale 76.8 6.8Female 70.5 8.8Cancer typeLung 65.4 17.1Skin 77.8 8.6Head and neck 78.6 12.3Endocrine 73.8 11.9Gastro‐intestinal 76.2 3.9Urological 88.4 7.8Gynecological 68.6 8.9Bone & soft tissue 91.5 7.0Hematological 75.8 10.0Other/primary
unknown81.8 22.2Treatment typeSurgery 97.9 4.9Surgery + RTb 81.6 7.0Surgery +
chemotherapy98.4 3.9Surgery + RTb +
chemotherapy81.5 4.7RTb 79.1 12.2RTb + chemotherapy 74.0 11.2RTb + hormone therapy 85.7 7.8Chemotherapy 100.0 19.0
VAN DER DONK ET AL. 9(Continued)Characteristic Response Rate, % Elevated Scorec, %Other 98.1 5.8Time since diagnosisLess than 2.5 y 88.5 6.4More than 2.5 y 84.1 8.1Time since treatment1 y 92.0 6.42 y 86.7 7.53 y 83.6 9.44 y 81.7 7.65 y 86.6 6.1Cancer recurrenceNo 84.9 7.3Yes 91.2 10.8aCategories were based on quartiles.
bRT = Radiotherapy Treatment.
cDetermined by PHQ‐9
A.2. | Screening letter for patients that was attached
to the screening questionnaire
Dear [MISS/SIR],
You are in follow‐up at our department because you have had can-
cer in the past. Whenever you visit our hospital for a medical check‐
up, our main aim is to find out how you are doing in terms of medical
health. Research, however, has shown that a diagnosis of cancer andtreatment can cause feelings of tension, sadness and insecurity and
that these emotional complaints can persist for a long while after can-
cer treatment has finished.
Questionnaire
Our department considers it important to also give attention to the
emotional consequences of having had cancer. For this reason, a short
questionnaire has been developed with questions regarding your cur-
rent mood. You can fill in this questionnaire within five minutes at
home via the internet. If you do not have internet access or if you
encounter other problems when filling in the questionnaire, you can
also make use of the attached paper questionnaire and send this back
using the prepaid return envelope (a stamp is not required).
To fill in the online questionnaire at home, you can visit:
[WEBSITE]
In the questionnaire, you will be asked about your security code.
Your personal security code is:
[SECURITY CODE]
Results
If the results from the questionnaire indicate that you have, for
instance, depressed or tensed feelings, you will be contacted. The
result of the questionnaire will also be in your medical records, making
the information also accessible for your medical practitioner. There-
fore, you can, if you want to, discuss the results of the questionnaire
with your medical practitioner. You can call us as well if you have
any questions. [PHONE NUMBER]
We would like to thank you in advance for your cooperation.
Kind regards,
[NAME]
